Caris Life Sciences, Inc. Common Stock (CAI) - Total Assets
Based on the latest financial reports, Caris Life Sciences, Inc. Common Stock (CAI) holds total assets worth $1.23 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Caris Life Sciences, Inc. Common Stock - Total Assets Trend (2003–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see Caris Life Sciences, Inc. Common Stock (CAI) total market value for the company's overall valuation and market capitalisation.
Caris Life Sciences, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Caris Life Sciences, Inc. Common Stock's total assets of $1.23 Billion consist of 88.6% current assets and 11.4% non-current assets. Review Caris Life Sciences, Inc. Common Stock debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 70.9% |
| Accounts Receivable | $112.14 Million | 10.0% |
| Inventory | $63.62 Million | 5.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $19.34 Million | 1.7% |
Asset Composition Trend (2003–2025)
This chart illustrates how Caris Life Sciences, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See CAI stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Caris Life Sciences, Inc. Common Stock's current assets represent 88.6% of total assets in 2025, an increase from 1.7% in 2003.
- Cash Position: Cash and equivalents constituted 70.9% of total assets in 2025, up from 1.7% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 10.0% of total assets.
Caris Life Sciences, Inc. Common Stock Competitors by Total Assets
Key competitors of Caris Life Sciences, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Caris Life Sciences, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.53 | 9.24 | 0.45 |
| Quick Ratio | 4.88 | 8.79 | 0.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $866.39 Million | $743.14 Million | $-256.13 Million |
Caris Life Sciences, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Caris Life Sciences, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.85 |
| Latest Market Cap to Assets Ratio | 6.03 |
| Asset Growth Rate (YoY) | 227.5% |
| Total Assets | $1.13 Billion |
| Market Capitalization | $6.79 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Caris Life Sciences, Inc. Common Stock's assets at a significant premium (6.03x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Caris Life Sciences, Inc. Common Stock's assets grew by 227.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Caris Life Sciences, Inc. Common Stock (2003–2025)
The table below shows the annual total assets of Caris Life Sciences, Inc. Common Stock from 2003 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.13 Billion | +227.48% |
| 2024-12-31 | $343.73 Million | -16.75% |
| 2023-12-31 | $412.90 Million | -42.45% |
| 2022-12-31 | $717.42 Million | -72.54% |
| 2020-12-31 | $2.61 Billion | -9.96% |
| 2019-12-31 | $2.90 Billion | -3.68% |
| 2018-12-31 | $3.01 Billion | +23.96% |
| 2017-12-31 | $2.43 Billion | +18.21% |
| 2016-12-31 | $2.06 Billion | +3.49% |
| 2015-12-31 | $1.99 Billion | +10.62% |
| 2014-12-31 | $1.80 Billion | +7.18% |
| 2013-12-31 | $1.68 Billion | +20.72% |
| 2012-12-31 | $1.39 Billion | +45.58% |
| 2011-12-31 | $953.37 Million | +55.41% |
| 2010-12-31 | $613.45 Million | +63.99% |
| 2009-12-31 | $374.08 Million | -9.34% |
| 2008-12-31 | $412.63 Million | +14.91% |
| 2007-12-31 | $359.10 Million | +26.89% |
| 2006-12-31 | $283.00 Million | +56.65% |
| 2005-12-31 | $180.66 Million | -0.71% |
| 2004-12-31 | $181.96 Million | -5.77% |
| 2003-12-31 | $193.10 Million | -- |
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more